Journal of Clinical Oncology
Articles in this Issue
A phase I dose-escalation study of a first-in-class HIF1 and HIF2 dual inhibitor R01 in patients with advanced tumors.
e15097 Background: Hypoxia Inducible Factors 1 and 2 (HIFs) are over-activated in nearly all tumors but not in normal tissues, making them attractive targ...
Use of aspirin for chemoprevention in Lynch syndrome: A systematic review and meta-analysis.
e15725 Background: Lynch syndrome is the most common hereditary colorectal cancer (CRC) that is caused by germline mutations in mismatch repair genes. Pre...
Targeting cancer leptomeningeal metastasis with allogeneic chimeric antigen receptor γδ T-cell therapy.
2533 Background: Leptomeningeal metastasis (LM) occurs in 1–10% of patients with advanced solid tumors during disease progression. LM significantly worsen...
A retrospective real-world study of first-line PD-(L)1 inhibitor use in patients with metastatic non-small cell lung cancer (mNSCLC).
e20563 Background: Programmed death ligand 1 (PD-[L]1) inhibitors such as retifanlimab have improved survival in patients with mNSCLC, yet these treatment...
Amivantamab treatment and intra-tumoral gene expression and immune cell changes in refractory metastatic colorectal cancer (mCRC): Whole transcriptome RNA-sequencing analysis from the OrigAMI-1 study.
3550 Background: Amivantamab (ami) is an FDA- and EMA-approved EGFR-MET bispecific antibody with immune cell–directing activity for EGFR...
Venetoclax as cytoreductive therapy in high-risk acute promyelocytic leukemia: A potential alternative to anthracyclines.
6521 Background: High-risk acute promyelocytic leukemia (APL) presents a significant mortality risk during induction therapy, primarily due to complicatio...
Targeting the PYGL with chicoric acid to normalize glucose metabolism to inhibit progress in NSCLC.
e15096 Background: Glucose metabolism reprogramming often drives the malignant progression of tumors, and targeted therapies against aberrant tumor metabo...
Cancer in adolescents and young adults: Role of schools in raising awareness.
e24070 Background: Patients diagnosed with cancer as adolescents or young adults (AYA: 15-39yo) have unique developmental needs (psychosocial, fertility p...
Drug-eluting transarterial chemoembolization combined with anlotinib for non-small cell lung cancer in the elderly: A multicenter retrospective study.
e20668 Background: Lung cancer is one of the malignant tumors with the highest morbidity and mortality in the world. Non-small cell lung cancer (NSCLC) ac...
First-in-human trial of SYS6010 combined with SYH2051 in patients with advanced gastrointestinal tumors.
3037 Background: SYS6010 is an antibody-drug conjugate (ADC) composed of an EGFR-specific antibody, a cleavable linker, and JS-1, a topoisomerase I inhibi...
Dynamic changes in target protein expression following treatment in NSCLC: Simultaneous evaluation of MET, TROP2, HER2, B7-H4, and MDM2 expression in paired biopsies.
8591 Background: Antibody-drug conjugates and bispecific antibodies targeting non-small cell lung cancer (NSCLC) tumor surface antigens are under developm...
Should we treat TP53-mutated high-risk myeloid neoplasms in older patients?
6538 Background: TP53 mutated ( TP53 mt ) high-risk myeloid neoplasm (HR-MN) confers a dismal prognosis in...
waveLINE-010: Zilovertamab vedotin plus R-CHP versus R-CHOP in untreated diffuse large B-cell lymphoma.
TPS7092 Background: Despite recent advances in the treatment of diffuse large B-cell lymphoma (DLBCL), 5-year survival rates range between 60% and 80%. Mo...
Deep learning to predict treatment response of immune checkpoint inhibitors from pretreatment chest X-rays in non–small-cell lung cancer.
e13628 Background: Despite the wide availability and cost-effectiveness of chest X-rays (CXRs), their potential as a biomarker for immune checkpoint inhib...
EMBER-Lung: Electronic medical record boosting molecular testing in early stage NSCLC.
8075 Background: Actionable alterations are identified in 30-40% of patients with advanced non-squamous (NSq) non-small cell lung cancer (NSCLC). Although...
Analyzing trends in vulvovaginal cancer mortality in the United States from 1999 to 2020.
e17654 Background: Vulvovaginal cancer’s (VC) representing distinct malignancies of the vulva and vagina are rare malignancies with significant mortality...
Patient outcomes in WSG-ADAPT according to NATALEE and MonarchE risk criteria.
601 Background: In HR+/HER2- high-risk early breast cancer (eBC), abemaciclib and ribociclib improve the efficacy of standard endocrine treatment (ET), as...
Analysis of gene mutations, TMB, and PD-L1 in relation to ICI response in HNSCC.
6027 Background: Immune checkpoint inhibitors (ICI) have changed the treatment of incurable advanced, recurrent, or metastatic (R/M) head and neck squamou...
Prediction of real-world progression free survival (rwPFS) using a multimodal machine learning (ML) model for patients with HR+ HER2- metastatic breast cancer (mBC) undergoing first line (1L) treatment with cyclin-dependent kinase 4 and 6 inhibitors (CDK4/6i) and endocrine therapy (ET).
e13088 Background: CDK4/6i combined with ET is 1L standard of care treatment for HR+/HER2- for mBC patients, however duration of response varies with some...
Eribulin plus anlotinib in advanced soft tissue sarcoma (ERAS): Updates on efficacy and biomarkers.
11502 Background: This study provides an updated evaluation of the efficacy and biomarker analysis of combination therapy using eribulin, a microtubule dy...
Temporal trends and disparities in cardiovascular mortality among breast cancer patients: A 25-year population analysis of the CDC WONDER database (1999-2023).
12026 Background: Breast cancer and cardiovascular disease (CVD) are leading causes of mortality among women in the United States. While advancements in b...
Clinical efficacy and safety of front-line CDK4/6 inhibitor therapy in HR+/HER2- advanced breast cancer patients with visceral metastases: A retrospective study.
e13074 Background: The introduction of CDK4/6 inhibitors (CDK4/6i) has significantly improved the prognosis of patients with hormone receptor-positive, HE...
First report of ROR2 directed therapy with a conditionally active antibody drug conjugate in advanced melanoma.
3077 Background: The receptor tyrosine-kinase like orphan receptors (ROR) are mediators of noncanonical WNT signaling and tissue patterning. ROR2 upregula...
Leveraging stimulated Raman histology-based cellularity for random forest prediction of glioblastoma recurrence.
2010 Background: Glioblastoma is a universally fatal diagnosis with extent of resection being one of the most significant predictors of overall and progre...
Circulating tumor DNA (ctDNA) analysis guiding adjuvant therapy in patients (pts) with colorectal cancer (CRC): Impact on fear of cancer recurrence (FCR).
11125 Background: ctDNA detection following curative intent treatment is highly prognostic, with potential to impact patient fear of cancer recurrence (FC...